4D Molecular Therapeutics Inc.
July 17, 2024 - by Joey Ramson
Biotech company $FDMT has faded pretty hard after starting the day up. The stock is currently down upwards of 30%. Earlier today the company released results from their PRISM Phase 2 Clinical Trial, which they described as positive, but clearly it wasn’t quite what the market was looking for.
